{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:48:05Z","timestamp":1761518885163,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2000,10,1]],"date-time":"2000-10-01T00:00:00Z","timestamp":970358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2000,10,1]],"date-time":"2000-10-01T00:00:00Z","timestamp":970358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2000,10]]},"DOI":"10.3816\/cbc.2000.n.019","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:04:44Z","timestamp":1221080684000},"page":"226-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Phase II Trial of Gemcitabine\/Doxorubicin\/Paclitaxel Administered Every Other Week in Patients with Metastatic Breast Cancer"],"prefix":"10.3816","volume":"1","author":[{"given":"Pedro","family":"S\u00e1nchez-Rovira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Ja\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Encarnaci\u00f3n","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Porras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Rosario","family":"Due\u00f1as","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bego\u00f1a","family":"Medina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicol\u00e1s","family":"Mohedano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximiliano","family":"Martos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CBC.2000.n.019_bib1","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0140-6736(98)03301-7","article-title":"Polychemotherapy for early breast cancer: an overview of the randomised trials","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.3816\/CBC.2000.n.019_bib2","series-title":"Diseases of the Breast","first-page":"669","article-title":"Treatment of metastatic disease","author":"Hong","year":"1996"},{"issue":"suppl 11","key":"10.3816\/CBC.2000.n.019_bib3","first-page":"16","article-title":"A phase I\/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer","volume":"23","author":"Amadori","year":"1996","journal-title":"Semin Oncol"},{"key":"10.3816\/CBC.2000.n.019_bib4","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1200\/JCO.1995.13.11.2688","article-title":"Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dosefinding and sequence-finding study","volume":"13","author":"Gianni","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2000.n.019_bib5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1200\/JCO.1996.14.1.95","article-title":"Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients","volume":"14","author":"Tolcher","year":"1996","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.3816\/CBC.2000.n.019_bib6","first-page":"28","article-title":"Paclitaxel plus vinorelbine in metastatic breast cancer patients with contraindications to receive anthracyclines","volume":"12","author":"Martin","year":"1998","journal-title":"Oncology (Huntingt)"},{"issue":"suppl 8","key":"10.3816\/CBC.2000.n.019_bib7","first-page":"37","article-title":"Docetaxel\/doxorubicin\/cyclophosphamide in the treatment of metastatic breast cancer","volume":"11","author":"Nabholtz","year":"1997","journal-title":"Oncology (Huntingt)"},{"key":"10.3816\/CBC.2000.n.019_bib8","first-page":"1a","article-title":"Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial","volume":"16","author":"Sledge","year":"1997","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 11","key":"10.3816\/CBC.2000.n.019_bib9","first-page":"23","article-title":"Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer","volume":"23","author":"Dombernowsky","year":"1996","journal-title":"Semin Oncol"},{"issue":"suppl 11","key":"10.3816\/CBC.2000.n.019_bib10","first-page":"S13","article-title":"Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer","volume":"24","author":"Hortobagyi","year":"1997","journal-title":"Semin Oncol"},{"issue":"suppl 17","key":"10.3816\/CBC.2000.n.019_bib11","first-page":"S26","article-title":"Paclitaxel plus doxorubicin in metastatic breast cancer: preliminary analysis of cardiotoxicity","volume":"24","author":"Martin","year":"1997","journal-title":"Semin Oncol"},{"key":"10.3816\/CBC.2000.n.019_bib12","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.1997.15.7.2510","article-title":"Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer","volume":"15","author":"Conte","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2000.n.019_bib13","first-page":"56","article-title":"Phase I trial of Zinecard, Adriamycin and escalating doses of Taxol in advanced breast cancer","volume":"46","author":"Sparano","year":"1997","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 3","key":"10.3816\/CBC.2000.n.019_bib14","first-page":"30","article-title":"Doxorubicin and paclitaxel (sequential combination) in the treatment of advanced breast cancer","volume":"11","author":"Amadori","year":"1997","journal-title":"Oncology (Huntingt)"},{"key":"10.3816\/CBC.2000.n.019_bib15","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1200\/JCO.1996.14.4.1185","article-title":"Phase I\/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer","volume":"14","author":"Gelmon","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2000.n.019_bib16","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1200\/JCO.1997.15.5.1880","article-title":"Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: an Eastern Cooperative Oncology Group study","volume":"15","author":"Sparano","year":"1997","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.3816\/CBC.2000.n.019_bib17","first-page":"19","article-title":"One-hour paclitaxel via weekly infusion: dose-density with enhanced therapeutic index","volume":"12","author":"Seidman","year":"1998","journal-title":"Oncology (Huntingt)"},{"issue":"suppl 17","key":"10.3816\/CBC.2000.n.019_bib18","first-page":"S17","article-title":"Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report","volume":"24","author":"Akerley","year":"1997","journal-title":"Semin Oncol"},{"key":"10.3816\/CBC.2000.n.019_bib19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2165\/00003495-199754030-00009","article-title":"Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer","volume":"54","author":"Noble","year":"1997","journal-title":"Drugs"},{"key":"10.3816\/CBC.2000.n.019_bib20","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.1997.15.11.3394","article-title":"Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer","volume":"15","author":"Stadler","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2000.n.019_bib21","first-page":"64a","article-title":"Difluorodeoxycytidine (gemcitabine): a phase II study in patients with advanced breast cancer","volume":"12","author":"Carmichael","year":"1993","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 5","key":"10.3816\/CBC.2000.n.019_bib22","first-page":"80","article-title":"Advanced breast cancer: a phase II trial with gemcitabine","volume":"31","author":"Possinger","year":"1998","journal-title":"Eur J Cancer"},{"issue":"suppl 5","key":"10.3816\/CBC.2000.n.019_bib23","first-page":"23","article-title":"Activity of gemcitabine in metastatic breast cancer patients previously treated with anthracycline containing regimens","volume":"7","author":"Spielmann","year":"1996","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2000.n.019_bib24","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1023\/A:1008286908930","article-title":"Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors","volume":"9","author":"Rothenberg","year":"1998","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2000.n.019_bib25","first-page":"97a","article-title":"Biweekly paclitaxel and gemcitabine in advanced breast cancer. Phase II trial and predictive value of HER2 extracellular domain (ECD)","volume":"19","author":"Colomer","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2000.n.019_bib26","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1200\/JCO.2000.18.13.2545","article-title":"Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial","volume":"18","author":"Perez-Manga","year":"2000","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.3816\/CBC.2000.n.019_bib27","first-page":"16","article-title":"Phase II biweekly paclitaxel, doxorubicin and gemcitabine as first line chemotherapy for metastatic breast cancer: preliminary results","volume":"9","author":"Lozano","year":"1998","journal-title":"Ann Oncol"},{"issue":"suppl 8","key":"10.3816\/CBC.2000.n.019_bib28","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/S0959-8049(97)85277-X","article-title":"Preliminary results from an early phase II trial of combination gemcitabine and paclitaxel in metastatic breast cancer","volume":"33","author":"Sanchez-Rovira","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.3816\/CBC.2000.n.019_bib29","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/jnci\/87.15.1169","article-title":"Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines","volume":"87","author":"Gianni","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2000.n.019_bib30","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1200\/JCO.1995.13.8.2056","article-title":"Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial","volume":"13","author":"Abrams","year":"1995","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"10.3816\/CBC.2000.n.019_bib31","first-page":"11","article-title":"Kinetic concepts in the systemic drug therapy of breast cancer","volume":"26","author":"Norton","year":"1999","journal-title":"Semin Oncol"},{"key":"10.3816\/CBC.2000.n.019_bib32","doi-asserted-by":"crossref","first-page":"88S","DOI":"10.1002\/j.1875-9114.1996.tb03631.x","article-title":"New approaches to adjuvant chemotherapy for breast cancer","volume":"16","author":"Hudis","year":"1996","journal-title":"Pharmacotherapy"},{"key":"10.3816\/CBC.2000.n.019_bib33","first-page":"678","article-title":"Paclitaxel and gemcitabine cell cycle interactions in non-small cell lung cancer cell lines","volume":"40","author":"Kroep","year":"1999","journal-title":"Proc Am Assoc Cancer Res"},{"issue":"suppl 2","key":"10.3816\/CBC.2000.n.019_bib34","first-page":"14","article-title":"The gemcitabine\/epirubicin\/paclitaxel combination in advanced breast cancer","volume":"27","author":"Gennari","year":"2000","journal-title":"Semin Oncol"},{"key":"10.3816\/CBC.2000.n.019_bib35","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1200\/JCO.1999.17.3.880","article-title":"Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer","volume":"17","author":"Sparano","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2000.n.019_bib36","first-page":"160a","article-title":"Phase II randomized trial of doxorubicin plus paclitaxel (AT) versus doxorubicin HCL liposome injection (DoxilR) plus paclitaxel (DT) in metastatic breast cancer","volume":"17","author":"Moore","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2000.n.019_bib37","first-page":"223","article-title":"Phase II trial of doxorubicin and docetaxel plus granulocyte-colony stimulating factor in metastatic breast cancer: An Eastern Cooperative Oncology Group study (E1196)","volume":"50","author":"Sparano","year":"1998","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2000.n.019_bib38","first-page":"146a","article-title":"TaxolR (T) plus doxorubicin (D) in the treatment of metastatic breast cancer (MBC) in ambulatory patients (Pts)","volume":"15","author":"Cazap","year":"1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2000.n.019_bib39","first-page":"126a","article-title":"Phase II trial of Taxol (T), doxorubicin (D) plus G-CSF in patients (pts) with metastatic breast cancer (MBC)","volume":"15","author":"Schwartsmann","year":"1996","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911701355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911701355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:06:31Z","timestamp":1761512791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820911701355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,10]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,10]]}},"alternative-id":["S1526820911701355"],"URL":"https:\/\/doi.org\/10.3816\/cbc.2000.n.019","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2000,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II Trial of Gemcitabine\/Doxorubicin\/Paclitaxel Administered Every Other Week in Patients with Metastatic Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CBC.2000.n.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2000 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}